Key facts for NCD 190.20
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 01/01/2005
- Implemented 03/11/2005
- Transmittal
- Transmittal 28
- Versions published
- 2
- Lab edit list
- 4,634 covered ICD-10
- 466 non-covered
TL;DR
NCD 190.20 sets Medicare's national policy for blood glucose testing under the benefit category "Diagnostic Laboratory Tests", effective 01/01/2005 and implemented 03/11/2005. Blood glucose values are often necessary for the management of patients with diabetes mellitus, where hyperglycemia and hypoglycemia are often present. They are also critical in the determination of control of blood glucose levels in the patient with impaired… As a laboratory NCD it carries a national ICD-10 edit list: 4,634 diagnosis codes support medical necessity and 466 are denied, applied automatically by every Medicare contractor to 3 procedure codes.
Item or service described
This policy is intended to apply to blood samples used to determine glucose levels. Blood glucose determination may be done using whole blood, serum or plasma. It may be sampled by capillary puncture, as in the fingerstick method, or by vein puncture or arterial sampling. The method for assay may be by color comparison of an indicator stick, by meter assay of whole blood or a filtrate of whole blood, using a device approved for home monitoring, or by using a laboratory assay system using serum or plasma. The convenience of the meter or stick color method allows a patient to have access to blood glucose values in less than a minute or so and has become a standard of care for control of blood glucose, even in the inpatient setting.
Indications and limitations of coverage
Indications
Blood glucose values are often necessary for the management of patients with diabetes mellitus, where hyperglycemia and hypoglycemia are often present. They are also critical in the determination of control of blood glucose levels in the patient with impaired fasting glucose (FPG 110-125 mg/dL), the patient with insulin resistance syndrome and/or carbohydrate intolerance (excessive rise in glucose following ingestion of glucose or glucose sources of food), in the patient with a hypoglycemia disorder such as nesidioblastosis or insulinoma, and in patients with a catabolic or malnutrition state. In addition to those conditions already listed, glucose testing may be medically necessary in patients with tuberculosis, unexplained chronic or recurrent infections, alcoholism, coronary artery disease (especially in women), or unexplained skin conditions (including pruritis, local skin infections, ulceration and gangrene without an established cause).
Many medical conditions may be a consequence of a sustained elevated or depressed glucose level. These include comas, seizures or epilepsy, confusion, abnormal hunger, abnormal weight loss or gain, and loss of sensation. Evaluation of glucose may also be indicated in patients on medications known to affect carbohydrate metabolism.
Effective January 1, 2005, the Medicare law expanded coverage to diabetic screening services. Some forms of blood glucose testing covered under this national coverage determination may be covered for screening purposes subject to specified frequencies. See 42 CFR 410.18 and section 90, chapter 18, of the Claims Processing Manual , for a full description of this screening benefit.
Limitations
Frequent home blood glucose testing by diabetic patients should be encouraged. In stable, non-hospitalized patients who are unable or unwilling to do home monitoring, it may be reasonable and necessary to measure quantitative blood glucose up to four times annually.
Depending upon the age of the patient, type of diabetes, degree of control, complications of diabetes, and other co-morbid conditions, more frequent testing than four times annually may be reasonable and necessary.
In some patients presenting with nonspecific signs, symptoms, or diseases not normally associated with disturbances in glucose metabolism, a single blood glucose test may be medically necessary. Repeat testing may not be indicated unless abnormal results are found or unless there is a change in clinical condition. If repeat testing is performed, a specific diagnosis code (e.g., diabetes) should be reported to support medical necessity. However, repeat testing may be indicated where results are normal in patients with conditions where there is a confirmed continuing risk of glucose metabolism abnormality (e.g., monitoring glucocorticoid therapy).
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.20 version 2. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 4,634 covered and 466 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.
3 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 82947 | CPT (descriptor licensed by AMA) |
| 82948 | CPT (descriptor licensed by AMA) |
| 82962 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 3 of the 3 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $3.28 to $5.04, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 82947 | $3.93 | $3.93 | national payment amount |
| 82948 | $5.04 | — | national payment amount |
| 82962 | $3.28 | — | national payment amount |
The first 40 of 4,634 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.
| ICD-10-CM | Description | Effective |
|---|---|---|
| A15.0 | Tuberculosis of lung | 2015-10-01 |
| A15.5 | Tuberculosis of larynx, trachea and bronchus | 2015-10-01 |
| A22.1 | Pulmonary anthrax | 2015-10-01 |
| A37.01 | Whooping cough due to Bordetella pertussis with pneumonia | 2015-10-01 |
| A37.11 | Whooping cough due to Bordetella parapertussis with pneumonia | 2015-10-01 |
| A37.81 | Whooping cough due to other Bordetella species with pneumonia | 2015-10-01 |
| A37.91 | Whooping cough, unspecified species with pneumonia | 2015-10-01 |
| A40.0 | Sepsis due to streptococcus, group A | 2015-10-01 |
| A40.1 | Sepsis due to streptococcus, group B | 2015-10-01 |
| A40.3 | Sepsis due to Streptococcus pneumoniae | 2015-10-01 |
| A40.8 | Other streptococcal sepsis | 2015-10-01 |
| A40.9 | Streptococcal sepsis, unspecified | 2015-10-01 |
| A41.01 | Sepsis due to Methicillin susceptible Staphylococcus aureus | 2015-10-01 |
| A41.02 | Sepsis due to Methicillin resistant Staphylococcus aureus | 2015-10-01 |
| A41.1 | Sepsis due to other specified staphylococcus | 2015-10-01 |
| A41.2 | Sepsis due to unspecified staphylococcus | 2015-10-01 |
| A41.3 | Sepsis due to Hemophilus influenzae | 2015-10-01 |
| A41.4 | Sepsis due to anaerobes | 2015-10-01 |
| A41.50 | Gram-negative sepsis, unspecified | 2015-10-01 |
| A41.51 | Sepsis due to Escherichia coli [E. coli] | 2015-10-01 |
| A41.52 | Sepsis due to Pseudomonas | 2015-10-01 |
| A41.53 | Sepsis due to Serratia | 2015-10-01 |
| A41.54 | Sepsis due to Acinetobacter baumannii | 2023-10-01 |
| A41.59 | Other Gram-negative sepsis | 2015-10-01 |
| A41.81 | Sepsis due to Enterococcus | 2015-10-01 |
| A41.89 | Other specified sepsis | 2015-10-01 |
| A41.9 | Sepsis, unspecified organism | 2015-10-01 |
| A42.7 | Actinomycotic sepsis | 2015-10-01 |
| A48.1 | Legionnaires' disease | 2015-10-01 |
| B25.0 | Cytomegaloviral pneumonitis | 2015-10-01 |
| B25.2 | Cytomegaloviral pancreatitis | 2015-10-01 |
| B37.2 | Candidiasis of skin and nail | 2015-10-01 |
| B37.31 | Acute candidiasis of vulva and vagina | 2022-10-01 |
| B37.32 | Chronic candidiasis of vulva and vagina | 2022-10-01 |
| B44.0 | Invasive pulmonary aspergillosis | 2015-10-01 |
| B48.8 | Other specified mycoses | 2015-10-01 |
| B77.81 | Ascariasis pneumonia | 2015-10-01 |
| B78.1 | Cutaneous strongyloidiasis | 2015-10-01 |
| C25.4 | Malignant neoplasm of endocrine pancreas | 2015-10-01 |
| C48.0 | Malignant neoplasm of retroperitoneum | 2015-10-01 |
466 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 3 codes added and 1 code removed against January 2026. CMS marked 6 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.
| ICD-10-CM | FY2027 description | Result |
|---|---|---|
| M86.8X71 | Other osteomyelitis, right ankle and foot | covered |
| M86.8X72 | Other osteomyelitis, left ankle and foot | covered |
| M86.8X79 | Other osteomyelitis, unspecified ankle and foot | covered |
| ICD-10-CM | Description | Was | Why |
|---|---|---|---|
| M86.8X7 | Other osteomyelitis, ankle and foot | covered | deleted from ICD-10-CM; replaced by M86.8X71, M86.8X72, M86.8X79 |
Codes on this NCD's list by release: October 2025: 2,696 · January 2026: 2,808 · October 2026: 2,810. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Local policies that build on this NCD
2 active Local Coverage Determinations cite NCD 190.20 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.
- Frequency of Laboratory Tests (L35099) · Novitas Solutions, Inc.
- LCD L38686: Implantable Continuous Glucose Monitors (I-CGM) · Wisconsin Physicians Service Insurance Corporation
How MACs bill NCD 190.20
A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 2 current articles in the Medicare Coverage Database name NCD 190.20, 2 of them with a covered ICD-10-CM list, from 2 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.
| Contractor | Articles |
|---|---|
| Wellpoint Federal | A58116 |
| Wisconsin Physicians Service Insurance Corporation | A58213 |
A58116: Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM)
Billing and Coding, effective 2026-09-10 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record
373 covered ICD-10-CM codes; 3 procedure codes: 0446T, 0447T, 0448T. Local policy: L38623 Implantable Continuous Glucose Monitors (I-CGM). Check a diagnosis for 0446T.
First covered codes: E08.00 Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC); E08.01 Diabetes mellitus due to underlying condition with hyperosmolarity with coma; E08.10 Diabetes mellitus due to underlying condition with ketoacidosis without coma; E08.11 Diabetes mellitus due to underlying condition with ketoacidosis with coma; E08.21 Diabetes mellitus due to underlying condition with diabetic nephropathy; E08.22 Diabetes mellitus due to underlying condition with diabetic chronic kidney disease; …
A58213: Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM)
Billing and Coding, effective 2026-09-10 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record
373 covered ICD-10-CM codes; 3 procedure codes: 0446T, 0447T, 0448T. Local policy: L35490 Category III Codes, L38686 Implantable Continuous Glucose Monitors (I-CGM). Check a diagnosis for 0446T.
First covered codes: E08.00 Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC); E08.01 Diabetes mellitus due to underlying condition with hyperosmolarity with coma; E08.10 Diabetes mellitus due to underlying condition with ketoacidosis without coma; E08.11 Diabetes mellitus due to underlying condition with ketoacidosis with coma; E08.21 Diabetes mellitus due to underlying condition with diabetic nephropathy; E08.22 Diabetes mellitus due to underlying condition with diabetic chronic kidney disease; …
Revision history
02/2005 - Added reference to screening benefits. Effective date 1/01/05. Implementation date 3/11/05. ( TN 28 ) (CR 3690)
07/2004 - Published NCD in NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.20
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.20
What does NCD 190.20 cover?
Blood glucose values are often necessary for the management of patients with diabetes mellitus, where hyperglycemia and hypoglycemia are often present. They are also critical in the determination of control of blood glucose levels in the patient with impaired fasting glucose (FPG 110-125 mg/dL), the patient with insulin resistance syndrome and/or carbohydrate intolerance… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.20 take effect?
The current version (2) is effective 01/01/2005, implemented 03/11/2005, published in transmittal 28. CMS lists 2 versions of this NCD.
Does a Local Coverage Determination override NCD 190.20?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.20?
The October 2026 laboratory NCD edit list contains 4,634 ICD-10-CM codes that support blood glucose testing (for example A15.0 Tuberculosis of lung; A15.5 Tuberculosis of larynx, trachea and bronchus; A22.1 Pulmonary anthrax) and 466 codes that deny. The list applies to 82947, 82948, 82962.
How often does the lab NCD code list for 190.20 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.